HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E4850 Tazemetostat hydrobromide Tazemetostat hydrobromide (EPZ-6438 hydrobromide) is a potent, selective, and orally available inhibitor of EZH2. It inhibits EZH2 with IC50 values of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat hydrobromide also inhibits EZH1 with an IC50 of 392 nM. Aug 06 2024
E1565 Iruplinalkib Iruplinalkib (WX-0593) is a highly selective oral inhibitor of ALK and ROS1 tyrosine kinase. It exhibits potent and promising antitumor activity in advanced non-small cell lung cancer (NSCLC) with ALK or ROS1 rearrangement. Aug 01 2024
E4632 Taminadenant Taminadenant (NIR178, PBF509) is a non-xanthine and non-furan antagonist of adenosine A2A receptor (A2AR). It can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with Kb values of 72.8 nM and 8.2 nM, respectively. It exhibits potential utility for Parkinson’s disease (PD) treatment. Aug 01 2024
E4636 W-7 hydrochloride W-7 hydrochloride is a potent antagonist of calmodulin (CaM) that inhibits Dengue virus (DENV) translation and replication. It also competitively inhibits Trypsin-treated Ca2+/calmodulin-dependent phosphodiesterase (Ca2+-PDE). It exhibits anti-proliferative and anti-tumor effect. Aug 01 2024
E1426 EAPB02303 EAPB02303 is a second-generation imiqualine that acts as a microtubule -disruptingagent and demonstrates anti-tumor effects and reduces tumor size in human melanoma xenografts. Aug 01 2024
E4841 Vorapaxar sulfate Vorapaxar sulfate (SCH 530348 sulfate) is a selective and orally active antagonist of protease-activated receptor (PAR-1), with a Ki value of 8.1 nM. Vorapaxar sulfate reduces thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner. Aug 01 2024
E4838 Cefuroxime Cefuroxime (Kefurox) is an orally active, second-generation, broad-spectrum cephalosporin antibiotic with increased stability to β-lactamase. Cefuroxime exhibits broad-spectrum activity against Gram-positive bacteria including penicillinase-producing staphylococci and non-β-lactamase-producing gram-negative bacteria. Aug 01 2024
E1403 Fumarate hydratase-IN-1 Fumarate hydratase-IN-1 is a small molecule cell-permeable inhibitor of fumarate hydratase. It induce alteration of TCA cycle metabolites, modulation of cytosolic processes, and substantial redox stress responses. Jul 29 2024
P1242 Proteinase K Proteinase K is a serine endoprotease, is used for isolating amyloid cores and is effective over a wide pH range (4–12), including in the presence of SDS or urea. It is commonly used as a preparative reagent for destruction of proteins, including DNAses and RNAses, in DNA and RNA preparations. Jul 29 2024
E1611 Atuzabrutinib Atuzabrutinib (SAR 444727, PRN473) is a reversible, selective inhibitor of Bruton's tyrosine kinase (Btk). It can effectively prevent neutrophil recruitment via inhibition of macrophage antigen‐1 signalling. Jul 25 2024
E1791 Zongertinib Zongertinib (BI 1810631, BI 764532) is a selective and potent inhibitor of human HER2 and EGFR tyrosine kinase that covalently binds to both wild-type and mutated HER2 receptors, including exon 20 insertion mutations, while sparing EGFR signaling. It exhibits effective and tolerable oral treatment for patients with HER2 aberration-positive solid tumors. Jul 25 2024
E1931 AD-5584 AD-5584 is a specific inhibitor of human acyl-CoA synthetase short chain family member 2 (ACSS2). It significantly reduces lipid storage, decreases colony formation, and increases cell death in vitro, while also confirming blood-brain barrier (BBB) permeability. Jul 25 2024
E1533 Lipofermata Lipofermata is an inhibitor of fatty acid transport protein 2 (FATP2) that demonstrates fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. It may offer therapeutic potential for diseases where lipotoxicity is a key factor. Jul 25 2024
E1877 BLU 451(LNG-451) BLU 451 (LNG-451) is a central nervous system (CNS)-penetrant, wild-type EGFR-sparing, covalent inhibitor of epidermal growth factor receptor (EGFR) exon 20 insertion (Ex20ins) with an IC50 of 7-78 nM. It also exhibits a potent anti-tumor efficacy. Jul 24 2024
E4827 Diphenhydramine Diphenhydramine is a first-generation antihistamine and sedative that acts as an antagonist of the H1 receptor and is used for treating acute allergic reactions. It is FDA-approved as an adjunct to epinephrine and corticosteroids and exhibits anticholinergic and antiemetic effects. Jul 23 2024
E1889 PCO371 PCO371 is a nonpeptidyl, orally active agonist of Parathyroid hormone type 1 receptor (PTHR1). It stimulates cAMP production in COS-7 cells with an EC50 of 2.4 μmol/L. It also acts as an osteoporosis drug and significantly enhances bone mineral density (BMD) and bone strength in the lumbar vertebrae of osteopenic ovariectomized (OVX) rats. It also restores normal serum calcium levels without increasing urinary calcium in hypocalcemic thyroparathyroidectomized (TPTX) rats. Jul 23 2024
E1985 YD23 YD23 is a PROTAC which induces the degradation of SMARCA2. It reduces chromatin accessibility in SMARCA4-deficient cells, affecting gene enhancers related to cell cycle and growth regulation, which leads to the downregulation of several cell cycle genes. It also selectively inhibits the growth of SMARCA4 mutant lung cancer cells in vitro. Jul 23 2024
E4835 Sumatriptan Sumatriptan (GR43175) is a selective agonist of 5-HT1D receptor, which is effectively used in the acute treatment of migraine. It causes a vasopressor response in the systemic and pulmonary arterial circulations and coronary artery vasoconstriction. Jul 23 2024
E4836 Bupivacaine Bupivacaine is a potent local anesthetic and sodium channel blocker used for local infiltration, nerve block, epidural, and intrathecal anesthesia. It significantly reduces cell viability and induces apoptosis. It also stimulates the production of ROS and activates MAPK pathways, which increases the expression of WDR35 in mouse neuroblastoma Neuro2a cells. It also activates NF-κB and c-Jun/AP-1 signalling pathways in Neuro2a cells. Jul 23 2024
E1961 NVL-655 NVL-655 is a selective inhibitor of anaplastic lymphoma kinase (ALK), with potential antineoplastic activity in the Ba/F3 xenograft model. It also exhibits significant inhibitory activity against ROS1, LTK, PYK2, TRKB, and FAK, with an IC50 ≤10-fold ALK and demonstrates high potency against specific ALK mutations, with an IC50 of <0.73 nM, 7 nM, 3 nM, 3 nM for G1202R, G1202R/L1196M, G1202R/G1269A and G1202R/L1198F respectively. Jul 23 2024